Answers are grounded in this paper and cite their sources.
Obesity is associated with increased risk of several cancers, yet its interactions with tumor-suppressor pathways vary by tissue and molecular context. Insulin resistance, lipid overload, inflammation, and oxidative stress may increase DNA damage and alter the selective environment in which genetically abnormal cells expand. Experimental evidence links obesity-related conditions with increased DNA damage in BRCA1/2-variant breast epithelium and with enhanced tumor development in selected TP53- and PTEN-deficient mouse models. Obesity-associated changes in DNA methylation and transcription have also been detected in cancer-relevant tissues; however, direct causal evidence that altered metabolic cofactors consistently silence specific canonical tumor-suppressor genes remains limited. Tumor-genomic analyses further suggest that adiposity can be associated with particular driver genotypes, without demonstrating that obesity directly causes those mutations. We integrate evidence on DNA-damage responses, epigenetic regulation, tumor-suppressor pathways, and the microenvironment, distinguishing direct experimental observations from human associations and mechanistic hypotheses. We also discuss how combining host metabolic phenotypes with tumor genomics and epigenomics may provide information beyond conventional molecular profiling. Clinically established synthetic-lethal therapies are separated from investigational epigenetic and metabolic approaches. This evidence-weighted framework supports tissue-specific investigation of obesity-related genomic vulnerability and clonal selection.
No takes yet. Share an insight, caveat, or question.
Ghosh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: